A British pilot study found that high-dose thiamine therapy reduced urinary albumin excretion (UAE) in patients with type 2 diabetes and microalbuminuria, according to a report in Diabetologia (2008; published online ahead of print).
Toviaz (fesoterodine fumarate), manufactured by Schwarz Pharma of Zwickau, Germany, and distributed by Pfizer, has been approved to help patients suffering from overactive bladder (OAB).
The FDA has issued an alert to health-care professionals and the public after receiving reports of complications from the use of surgical mesh to treat pelvic organ prolapse (POP) and stress urinary incontinence (SUI).
Sanofi-aventis has received approval for Apidra (insulin glulisine [rDNA origin] injection) to improve glycemic control in children aged four years and older with diabetes mellitus.
Vaprisol (conivaptan hydrochloride injection) Premixed in 5% Dextrose, a new formulation of Vaprisol developed by Astellas Pharma US, Inc., has been approved for the treatment of both euvolemic and hypervolemic hyponatremia in hospitalized patients.
Bacteremia duration does not accurately predict which hemodialysis (HD) patients will develop endocarditis, according to researchers.
Two new studies have linked early signs of kidney disease to higher risks for cardiovascular disease and diabetes.
Bisphosphonate-associated osteonecrosis of the jaw (BP-ONJ) may be an underestimated problem in prostate cancer patients treated with zoledronate, German investigators suggest.
Data from a German study suggest that IV-administered epoetin zeta—a new erythropoietin preparation—is safe for maintenance treatment of anemia in patients with end-stage renal disease.
Patients with symptomatic renal cell carcinoma (RCC) have worse survival than those who have asymptomatic RCC detected incidentally, according to researchers from the Czech Republic.
